Literature DB >> 18753413

Divergent transforming growth factor-beta signaling in hepatic stellate cells after liver injury: functional effects on ECE-1 regulation.

Al-Karim Khimji1, Rong Shao, Don C Rockey.   

Abstract

In liver wound healing, transforming growth factor-beta (TGF-beta) plays a critical role in stellate cell activation as well as signaling cascades in the fibrogenic response to injury. We postulate that the TGF-beta-dependent downstream signaling pathway may vary according to the mechanism of stellate cell activation; this study was undertaken to ascertain whether the downstream signaling pathways mediated by TGF-beta vary in different liver injury models. We measured Smad3 and MAP kinase activation after isolating stellate cells from rat livers injured by either bile duct ligation (BDL) or repeated carbon tetrachloride (CCl(4)) administration. Phospho-Smad3 was dramatically up-regulated in stellate cells after CCl(4) injury, but not after BDL-induced injury. TGF-beta signaling in stellate cells activated after BDL was mediated prominently through ERK activation, whereas activation induced by CCl(4) injury or culture led to a cross-signaling mechanism involving both Smad3 and p38. The divergent Smad signaling pathways observed appeared to be attributable to the differential regulation of the early growth response gene-1 (Egr-1), an apparent negative transcriptional factor for Smad3 in our system. In addition, inhibition of ERK activation in stellate cells from BDL-injured liver led to a decrease in expression of endothelin-converting enzyme-1, a critical regulator of endothelin-1. We speculate that TGF-beta signaling proceeds through differential signaling pathways depending on the mechanism of liver injury that leads to stellate cell activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753413      PMCID: PMC2527071          DOI: 10.2353/ajpath.2008.071121

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  57 in total

1.  Appearance of denuded hepatic stellate cells and their subsequent myofibroblast-like transformation during the early stage of biliary fibrosis in the rat.

Authors:  L H Tao; H Enzan; Y Hayashi; E Miyazaki; T Saibara; M Hiroi; M Toi; N Kuroda; K Naruse; Y L Jin; L M Guo
Journal:  Med Electron Microsc       Date:  2000

2.  Morphology of liver repair following cholestatic liver injury: resolution of ductal hyperplasia, matrix deposition and regression of myofibroblasts.

Authors:  G A Ramm; S C Carr; K R Bridle; L Li; R S Britton; D H Crawford; C A Vogler; B R Bacon; T F Tracy
Journal:  Liver       Date:  2000-10

3.  The role of Smad3 in mediating mouse hepatic stellate cell activation.

Authors:  B Schnabl; Y O Kweon; J P Frederick; X F Wang; R A Rippe; D A Brenner
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

4.  Activation of B-Raf and regulation of the mitogen-activated protein kinase pathway by the G(o) alpha chain.

Authors:  V Antonelli; F Bernasconi; Y H Wong; L Vallar
Journal:  Mol Biol Cell       Date:  2000-04       Impact factor: 4.138

5.  Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbeta signal transduction during transdifferentiation of hepatic stellate cells.

Authors:  S Dooley; B Delvoux; M Streckert; L Bonzel; M Stopa; P ten Dijke; A M Gressner
Journal:  FEBS Lett       Date:  2001-07-27       Impact factor: 4.124

6.  In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis.

Authors:  J George; D Roulot; V E Koteliansky; D M Bissell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

7.  High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis.

Authors:  T A McCaffrey; C Fu; B Du; S Eksinar; K C Kent; H Bush; K Kreiger; T Rosengart; M I Cybulsky; E S Silverman; T Collins
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

8.  Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension.

Authors:  Q Yu; R Shao; H S Qian; S E George; D C Rockey
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

9.  TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells.

Authors:  B Schnabl; C A Bradham; B L Bennett; A M Manning; B Stefanovic; D A Brenner
Journal:  Hepatology       Date:  2001-11       Impact factor: 17.425

10.  Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture.

Authors:  Zhaodong Li; Jonathan A Dranoff; Erick P Chan; Masayuki Uemura; Jean Sévigny; Rebecca G Wells
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

View more
  12 in total

1.  Mapping the extracellular and membrane proteome associated with the vasculature and the stroma in the embryo.

Authors:  Fabienne Soulet; Witold W Kilarski; Florence Roux-Dalvai; John M J Herbert; Izabela Sacewicz; Emmanuelle Mouton-Barbosa; Roy Bicknell; Patricia Lalor; Bernard Monsarrat; Andreas Bikfalvi
Journal:  Mol Cell Proteomics       Date:  2013-05-14       Impact factor: 5.911

2.  Hepatic stellate cells retain retinoid-laden lipid droplets after cellular transdifferentiation into activated myofibroblasts.

Authors:  Loretta L Jophlin; Yiannis Koutalos; Chunhe Chen; Vijay Shah; Don C Rockey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-07-19       Impact factor: 4.052

Review 3.  Endothelin and hepatic wound healing.

Authors:  Al-karim Khimji; Don C Rockey
Journal:  Pharmacol Res       Date:  2011-03-21       Impact factor: 7.658

4.  Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition.

Authors:  Johannes Kluwe; Jean-Philippe Pradere; Geum-Youn Gwak; Ali Mencin; Samuele De Minicis; Christoph H Osterreicher; Jordi Colmenero; Ramon Bataller; Robert F Schwabe
Journal:  Gastroenterology       Date:  2009-09-24       Impact factor: 22.682

5.  Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease.

Authors:  David Briskey; Mandy Heritage; Lesley-Anne Jaskowski; Jonathan Peake; Glenda Gobe; V Nathan Subramaniam; Darrell Crawford; Catherine Campbell; Luis Vitetta
Journal:  Therap Adv Gastroenterol       Date:  2016-05-01       Impact factor: 4.409

6.  Role of Smad3 in platelet-derived growth factor-C-induced liver fibrosis.

Authors:  Jung Il Lee; Jocelyn H Wright; Melissa M Johnson; Renay L Bauer; Kristina Sorg; Sebastian Yuen; Brian J Hayes; Lananh Nguyen; Kimberly J Riehle; Jean S Campbell
Journal:  Am J Physiol Cell Physiol       Date:  2015-12-02       Impact factor: 4.249

Review 7.  Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies.

Authors:  Don C Rockey
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-07       Impact factor: 11.382

8.  Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway.

Authors:  Jin-Xing Du; Ming-Yu Sun; Guang-Li Du; Feng-Hua Li; Cheng Liu; Yong-Ping Mu; Gao-Feng Chen; Ai-Hua Long; Yan-Qin Bian; Jia Liu; Cheng-Hai Liu; Yi-Yang Hu; Lie-Ming Xu; Ping Liu
Journal:  BMC Complement Altern Med       Date:  2012-04-03       Impact factor: 3.659

9.  Smooth muscle α actin (Acta2) and myofibroblast function during hepatic wound healing.

Authors:  Don C Rockey; Nate Weymouth; Zengdun Shi
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

10.  Involvement of TGF-β1/Smad3 Signaling in Carbon Tetrachloride-Induced Acute Liver Injury in Mice.

Authors:  Liman Niu; Xueling Cui; Yan Qi; Dongxue Xie; Qian Wu; Xinxin Chen; Jingyan Ge; Zhonghui Liu
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.